NCT06301893 Uganda Sickle Surveillance Study (US-3)
| NCT ID | NCT06301893 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Condition | Sickle Cell Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000,000 participants |
| Start Date | 2013-09-07 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000,000 participants in total. It began in 2013-09-07 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is estimated that over 250,000 babies are born with sickle cell disease (SCD) annually in sub-Saharan Africa, and only 10% - 50% of them survive beyond five years of age. Data describing the magnitude of the sickle cell problem are lacking in most African countries. The available data on prevalence were mainly from older studies and small numbers of hospitalized patients. In Uganda, approximately 25,000 children are born with SCD but 70-80% die before their 5th birthday. Lehmann and Raper found 'sicklaemia' prevalence of 0.8% and 45% in the Sebei and Bambaa ethnic groups, respectively. A recent study found a SCT and SCD prevalence of 3% - 19% and 0% - 3%, respectively but this study addressed only 5 of Uganda's 111 districts and used a small convenience sample of children aged 6 - 60 months. The objective of this study is to determine the prevalence and map out the burden of SCT and SCD in Uganda.
Eligibility Criteria
Inclusion Criteria: * Up to 1,000,000 samples may be collected during 2015 - 2030 following primary analysis based on surveillance findings. Exclusion Criteria: * Repeat samples on the same individuals during the study period will be excluded.
Contact & Investigator
Russell Ware, MD, PhD
PRINCIPAL INVESTIGATOR
Children's Hospital Medical Center, Cincinnati
Frequently Asked Questions
Who can join the NCT06301893 clinical trial?
This trial is open to participants of all sexes, up to 12 Months, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06301893 currently recruiting?
Yes, NCT06301893 is actively recruiting participants. Contact the research team at teresa.latham@cchmc.org for enrollment information.
Where is the NCT06301893 trial being conducted?
This trial is being conducted at Kampala, Uganda, Kampala, Uganda, Kampala, Uganda, Kampala, Uganda.
Who is sponsoring the NCT06301893 clinical trial?
NCT06301893 is sponsored by Children's Hospital Medical Center, Cincinnati. The principal investigator is Russell Ware, MD, PhD at Children's Hospital Medical Center, Cincinnati. The trial plans to enroll 1,000,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.